CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 26.44×, higher than 95% of its Biotechnology peers (median 3.43×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
10.21BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.3430xvs all stocks
52-Week Change
257.05%vs all stocks
Market Capitalization
10.21BUSDvs all stocks (USD)
Enterprise Value
9.20BUSDvs all stocks (USD)
Forward P/E
-25.75xvs Biotechnology peers
Price to Book (MRQ)
8.47xvs Biotechnology peers
Enterprise to EBITDA
-28.55xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-20.30%vs Biotechnology peers
Return on Equity (TTM)
-32.46%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Aug 26, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-322.12MUSDvs all stocks (USD)
Net Income (TTM)
-294.37MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-243.89MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-145.62MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-285.60MUSDvs all stocks (USD)
Pre-tax Income
-255.56MUSDFY2025 · Dec 31, 2025Income Tax Expense
278.00KUSDFY2025 · Dec 31, 2025Net Income
-255.84MUSDFY2025 · Dec 31, 2025EBIT
-285.60MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-284.18MUSDFY2025 · Dec 31, 2025Research & Development
214.71MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
69.75MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
30.03MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-255.84MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-216.77MUSDFY2025 · Dec 31, 2025Free Cash Flow
-221.92MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
131.55MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-255.84MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.42MUSDFY2025 · Dec 31, 2025Stock-based Compensation
46.28MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.68MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
150.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-12.45MUSDFY2025 · Dec 31, 2025Capital Expenditures
-5.15MUSDFY2025 · Dec 31, 2025Purchase of Investments
-642.30MUSDFY2025 · Dec 31, 2025Sale of Investments
467.87MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-179.57MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
389.63MUSDFY2025 · Dec 31, 2025Shares Outstanding
74.88MSharesUpdated Aug 26, 2026Float Shares
58.44MSharesUpdated Aug 26, 2026Shares Short
4.22MSharesUpdated Aug 26, 2026Short Ratio
2.71daysvs all stocks
Short % of Shares Outstanding
7.19%vs all stocks
% Held by Insiders
2.31%vs all stocks
% Held by Institutions
110.16%vs all stocks
Total Cash (MRQ)
971.93MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
12.89USDUpdated Aug 26, 2026Total Debt (MRQ)
6.83MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0057xvs Biotechnology peers
Current Ratio (MRQ)
26.44xvs Biotechnology peers
Book Value per Share (MRQ)
15.91USDUpdated Aug 26, 2026Total Assets
937.13MUSDvs all stocks (USD)
Total Current Assets
741.36MUSDFY2025 · Dec 31, 2025Total Liabilities
33.25MUSDFY2025 · Dec 31, 2025Total Non-current Assets
195.78MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
5.34MUSDFY2025 · Dec 31, 2025Total Current Liabilities
27.91MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
131.55MUSDFY2025 · Dec 31, 2025Other Short-term Investments
598.64MUSDFY2025 · Dec 31, 2025Accounts Payable
1.22MUSDFY2025 · Dec 31, 2025Short-term Debt
3.50MUSDFY2025 · Dec 31, 2025Long-term Debt
5.34MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-561.76MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
903.88MUSDvs all stocks (USD)
52-Week Low
35.39USDUpdated Aug 26, 202652-Week High
134.99USDUpdated Aug 26, 202652-Week Change
257.05%vs all stocks
Beta
0.3430xvs all stocks
50-Day MA
128.40USDUpdated Aug 26, 2026200-Day MA
88.90USDUpdated Aug 26, 2026Avg 10-Day Volume
1.22MSharesUpdated Aug 26, 2026Avg 30-Day Volume
1.20MSharesUpdated Aug 26, 2026Diluted EPS (TTM)
-4.34USDUpdated Aug 26, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 26.44×, higher than 95% of its Biotechnology peers (median 3.43×)Significant
Current ratio: 26.44Industry median: 3.43Industry P95: 17.10Peers compared: 24.00
Debt-to-equity is 0.01×, lower than 95% of its Biotechnology peers (median 0.24×)Notable
Debt-to-equity: 0.01Industry median: 0.24Industry P5: 0.01Peers compared: 24.00
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.58
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 32,166,921.735
Market cap is $10.21B, above the global median of $1.18BNotable
Market cap (USD): 10,212,546,083Global Median: 1,179,398,897.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Abivax SA
Tier 1ProductionApproval-Gated PipelineRule
Dr. Reddy's Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Laurus Labs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Praxis Precision Medicines Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ionis Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bio-Rad Laboratories Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Insulet Corporation
Tier 1ProductionApproval-Gated PipelineRule
RemeGen Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Lupin Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kymera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Pulse Biosciences Inc.
2 interpretationsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration
Largan Precision Co., Ltd.
2 interpretationsLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration